caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a nutritional supplement, a cholesterol translocation, and a emulsifier, and it impacts diabetic heart disease. The molecule is a apoptosis, energy source, membrane stabilizer, stabilizing cytochrome oxidase that impacts barth syndrome. The molecule is a food additive and a energy storage, impacting bot... | CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | [
"Nutritional supplement",
"Cholesterol translocation",
"Emulsifier",
"Diabetic heart disease",
"Apoptosis",
"Energy source",
"Barth syndrome",
"Membrane stabilizer",
"Stabilizing cytochrome oxidase",
"food additive",
"Aging",
"Energy storage",
"Tangier disease",
"Proton trap for oxidative ... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement, apoptosis, emulsifier, surfactant. The molecule is a membrane stabilizer, a stabilizing mitochondrial structure, and a energy storage, it impacts non-alcoholic fatty liver disease and is smooth. The molecule is a food additive and a cholesterol translocation, impacting both agi... | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"Nutritional supplement",
"Apoptosis",
"Emulsifier",
"surfactant",
"Smooth",
"Membrane stabilizer",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Energy storage",
"food additive",
"Aging",
"Tangier disease",
"Cholesterol translocation",
"Energy source",
"Ba... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and tangier disease. The molecule is a cholesterol translocation and a apoptosis that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)C | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a nampt inhibitor and a cancer treatment. | Cc1ccc(S(=O)(=O)n2ccnc2C2C=C2CO)cc1 | [
"nampt inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule has A 1% concn or more is liable to produce a sweetish taste.. The molecule has Practically odorless. When heated to decomposition it emits toxic fumes of oxides of nitrogen and sodium oxide. | NC(CCC(=O)O)C(=O)[O-].O.[Na+] | [
"taste_evaluation",
"Odor_evaluation",
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, non-alcoholic fatty liver disease, parkinson's disease, and diabetes mellitus type 2. | CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCc2oc(CCC)c(C)c2C)COP(=O)(O)OCCN)[C@@H](O)C[C@H]1O | [
"nutrient",
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease",
"Parkinson's disease",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a mitochondrial nadh:ubiquinone reductase inhibitor. | CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(=O)CC4CC(=O)CCC4(C)C3CC(=O)C12C | [
"mitochondrial NADH:ubiquinone reductase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts tangier disease and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source that impacts bleeding, hyperthyroidism, seizure, and uremia. The molecule is a human metabolite that impacts confusion, coma, cardiovascular disease, chronic kidney disease, and weight loss. The molecule is a emulsifier that impacts psychosis, vomiting, agitation, and nausea. The molecul... | Oc1cc(O)cc(/C=C/c2ccc(O)c(O)c2)c1 | [
"Energy source",
"Bleeding",
"Hyperthyroidism",
"Seizure",
"Uremia",
"Confusion",
"human metabolite",
"Coma",
"Cardiovascular disease",
"Chronic kidney disease",
"Weight loss",
"Psychosis",
"Emulsifier",
"Vomiting",
"Agitation",
"Nausea",
"surfactant",
"Kidney disease",
"Cirrhosi... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Thermal decomposition of 1,1,1-trichloroethane occurs below 260 °c, while large amounts of hydrogen chloride and trace amount of phosgene form at temperatures above that level. The molecule is a human xenobiotic metabolite with a Sweetish. | CC(Cl)(Cl)Cl | [
"Decomposition_evaluation",
"Odor_evaluation",
"human xenobiotic metabolite"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC(=O)OCC1OC(Oc2c(-c3ccc(O)c(O)c3)oc3cc(OC4OC(C)C(O)C(O)C4O)cc(O)c3c2=O)C(O)C(O)C1O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, energy source, fat storage that impacts obesity, cancer, and pancreatitis. The molecule is a inflammatory and membrane stabilizer, and it impacts metabolic syndrome. The molecule is a nutrient and thyroxine treatment, impacting both atherosclerosis and cardiovascular disease. | CCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)CC | [
"Energy storage",
"Energy source",
"Obesity",
"Cancer",
"Pancreatitis",
"Fat storage",
"inflammatory",
"Membrane stabilizer",
"Metabolic syndrome",
"Thyroxine treatment",
"nutrient",
"Atherosclerosis",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and a fat storage that impacts atherosclerosis, cardiovascular disease, cancer, and pancreatitis. The molecule is a energy storage and energy source, and it impacts obesity. The molecule is a membrane stabilizer and inflammatory, belonging to the thyroxine treatment class of molecules, and im... | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)CC | [
"Atherosclerosis",
"Cardiovascular disease",
"nutrient",
"Fat storage",
"Cancer",
"Pancreatitis",
"Energy storage",
"Obesity",
"Energy source",
"Metabolic syndrome",
"Membrane stabilizer",
"Thyroxine treatment",
"inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, non-alcoholic fatty liver disease, alzheimer's disease, and diabetes mellitus type 2. | CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CC1OC1CCCCC)COP(=O)(O)OCCN | [
"nutrient",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, apoptosis that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts diabetic heart disease, barth syndrome, and aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Barth syndrome",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both cardiovascular disease and atherosclerosis. The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting both metabolic syndrome and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Cardiovascular disease",
"Fat storage",
"Atherosclerosis",
"nutrient",
"Metabolic syndrome",
"Thyroxine treatment",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts seizure, alzheimer's disease, and colorectal cancer. It has an effect on stomach cancer, and impacts parkinson's disease, cardiovascular disease, and diabetes mellitus. | CC/C=C\C[C@@H](O)/C=C/C=C/C=C\C=C/[C@H](O)[C@@H](O)CCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCCCCCCCC/C=C\CCCCCC | [
"Seizure",
"Breast cancer",
"Alzheimer's Disease",
"Colorectal cancer",
"Parkinson's disease",
"Stomach cancer",
"Cardiovascular disease",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, a stabilizing cytochrome oxidase, and a food additive, and it impacts aging. The molecule is a surfactant, nutritional supplement, energy source, stabilizing mitochondrial structure that impacts diabetic heart disease. The molecule is a emulsifier and smooth, impacting both non-alcoholic fa... | CC(C)CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"food additive",
"Aging",
"surfactant",
"Nutritional supplement",
"Energy source",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Emulsifier",
"Smooth",
"Barth syndrome... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti depressant. | C=CCN1C(=S)Nc2ccc(Cl)cc2C1(O)c1ccccc1 | [
"anti depressant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a thyroxine treatment and fat storage, and it impacts pancreatitis. The molecule is a nutrient that impacts atherosclerosis, metabolic syndrome, and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Pancreatitis",
"Thyroxine treatment",
"Fat storage",
"nutrient",
"Atherosclerosis",
"Metabolic syndrome",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, and aging. The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Diabetic heart disease",
"Cholesterol translocation",
"Aging",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts parkinson's disease, seizure, cardiovascular disease, and colorectal cancer. It has an effect on stomach cancer, and impacts diabetes mellitus, alzheimer's disease, and breast cancer. | CCCCC/C=C\C/C=C\C/C=C\CC1OC1CCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Parkinson's disease",
"Seizure",
"Cardiovascular disease",
"Colorectal cancer",
"Diabetes mellitus",
"Alzheimer's Disease",
"Stomach cancer",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, and aging. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C=C/CCCCCC | [
"Apoptosis",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts diabetes treatment. | COC(=O)C(N)CC1=COC=C(C2=CC=CCC2c2ccc(OC(C)=O)cc2)O1 | [
"diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition it emits very toxic fumes of oxides of sulfur and oxides of nitrogen. The molecule is a dopamine uptake inhibitor with a Practically odorless. The molecule is a phenothiazine antipsychotic drug and a anti emetic with a Slightly bitter; pleasant aftertaste. | CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1 | [
"Decomposition_evaluation",
"dopamine uptake inhibitor",
"Odor_evaluation",
"taste_evaluation",
"phenothiazine antipsychotic drug",
"anti emetic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease and barth syndrome. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Tangier disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti bacterial. | COc1ccc2nccc(CCCC=O)c2c1 | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pi3 kinase inhibitor. | CC1CCC(CN(C)c2cc(-c3ccc(N)cc3)nc(-c3ccc(N)cc3)n2)O1 | [
"pi3 kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement, a proton trap for oxidative phosphorylation, and a energy source, and it impacts tangier disease. The molecule is a emulsifier, a food additive, and a stabilizing cytochrome oxidase, it impacts diabetic heart disease and is smooth. The molecule is a surfactant, a stabilizing mi... | CC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Nutritional supplement",
"Proton trap for oxidative phosphorylation",
"Energy source",
"Tangier disease",
"Emulsifier",
"food additive",
"Diabetic heart disease",
"Smooth",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"surfactant",
"Stabilizing mitochondrial structure",
"Energy stora... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, musty, green, metallic, rooty. The molecule is a flavoring agent, fruity, tropical, blackcurrant, sulfury. | CC/C=C/CC(=O)OC(COC(=O)CCCCCCCCCCC)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O | [
"musty",
"green",
"metallic",
"rooty",
"nutrient",
"Flavoring agent",
"fruity",
"tropical",
"blackcurrant",
"sulfury"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a syk inhibitor and belongs to the cancer treatment class of molecules. | Cn1c(=O)c(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccc(C(C=N)=CN)cc21 | [
"syk inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Apoptosis",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts diabetic heart disease and aging. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a obesity treatment and belongs to the diabetes treatment class of molecules. | CN(c1cccc2c1NC(C(=O)O)C2)S(=O)(=O)c1ccccn1 | [
"diabetes treatment",
"obesity treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts seizure, stomach cancer, and alzheimer's disease. It has an effect on colorectal cancer, and impacts diabetes mellitus, cardiovascular disease, and parkinson's disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCC[C@@H](O)/C=C\C=C\C=C\[C@@H](O)C/C=C\CCCCC | [
"Seizure",
"Breast cancer",
"Stomach cancer",
"Alzheimer's Disease",
"Diabetes mellitus",
"Colorectal cancer",
"Cardiovascular disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing mitochondrial structure that impacts aging. The molecule is a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | [
"Apoptosis",
"Aging",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a anti bacterial and a anti fungal. | CC1CC1COC(=O)C(C)N(C)C | [
"anti bacterial",
"anti fungal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is cancer treatment. | Cc1cc(Nc2cc3c(ccn3S(=O)(=O)c3ccccc3C#N)cn2)ccc1N1CCNCC1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, and tangier disease. The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts diabetic heart disease and aging. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on stomach cancer, and impacts diabetes mellitus, cardiovascular disease, and breast cancer. It has an effect on colorectal cancer, and impacts alzheimer's disease, seizure, and parkinson's disease. | CCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCC/C=C\CC1OC1CCCCC | [
"Stomach cancer",
"Diabetes mellitus",
"Cardiovascular disease",
"Breast cancer",
"Alzheimer's Disease",
"Colorectal cancer",
"Seizure",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts tangier disease and barth syndrome. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts aging and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Aging",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts barth syndrome. The molecule is a apoptosis that impacts tangier disease, non-alcoholic fatty liver disease, aging, and diabetic heart disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a apoptosis that impacts barth syndrome, aging, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome",
"Apoptosis",
"Aging",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, aging, and tangier disease. The molecule is a stabilizing cytochrome oxidase, apoptosis, proton trap for oxidative phosphorylation that impacts diabetic heart disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor. | CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1NC(C)c1ccccc1 | [
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation that impacts diabetic heart disease and barth syndrome. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts non-alcoholic fatty liver disease, aging, and tangier disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Aging",
"Tangier disease",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts tangier disease and barth syndrome. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both atherosclerosis and cardiovascular disease. The molecule is a nutrient and thyroxine treatment, impacting both pancreatitis and metabolic syndrome. | CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC | [
"Fat storage",
"Atherosclerosis",
"Cardiovascular disease",
"Pancreatitis",
"Thyroxine treatment",
"nutrient",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pi3k inhibitor and is cancer treatment. | C=C(Nc1cnc(Cl)nc1)NC(C1=C(C)c2cc(F)ccc2C1)C(C)C | [
"cancer treatment",
"pi3k inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, fat storage, inflammatory, and energy source, impacts atherosclerosis, and is thyroxine treatment. It has an effect on cancer, impacting both obesity and pancreatitis. The molecule is a nutrient and a energy storage, impacting both metabolic syndrome and cardiovascular disease. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Membrane stabilizer",
"Fat storage",
"Thyroxine treatment",
"inflammatory",
"Energy source",
"Atherosclerosis",
"Obesity",
"Pancreatitis",
"Cancer",
"Metabolic syndrome",
"nutrient",
"Cardiovascular disease",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a thyroxine treatment, energy source, fat storage, energy storage that impacts obesity and metabolic syndrome. The molecule is a membrane stabilizer that impacts both atherosclerosis and cardiovascular disease. The molecule is a inflammatory and a nutrient, with effects on cancer and impacts on pancreat... | CCC(C)CCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Thyroxine treatment",
"Obesity",
"Energy source",
"Metabolic syndrome",
"Fat storage",
"Energy storage",
"Atherosclerosis",
"Cardiovascular disease",
"Membrane stabilizer",
"inflammatory",
"nutrient",
"Pancreatitis",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a hyperproliferative disease treatment and a pim kinase inhibitor. | c1cc(-c2n[nH]c3cnc(-c4cnn(CC5COC5)c4)cc23)nc(N2CCNCC2)c1 | [
"hyperproliferative disease treatment",
"pim kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a cholesterol translocation that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cardiovascular disease, atherosclerosis, and metabolic syndrome. The molecule is a nutrient and a fat storage, impacting both pancreatitis and thyroxine treatment. | CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COCCCCCCCCCCCCCCCCCC)COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC | [
"Cardiovascular disease",
"Atherosclerosis",
"Metabolic syndrome",
"Pancreatitis",
"nutrient",
"Fat storage",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts aging, non-alcoholic fatty liver disease, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts tangier disease, diabetic heart disease, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects both breast cancer and cervical cancer, and also impacts atherosclerosis and ulcerative colitis. | CCCCC/C=C\C=C\C(=O)CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C | [
"Breast cancer",
"Atherosclerosis",
"Ulcerative colitis",
"nutrient",
"Cervical cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, barth syndrome, and tangier disease. | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Cholesterol translocation",
"Barth syndrome",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti microbial and is anti tumor. | CCCCCCCCCCCCCCCCCCOCC(COP(=O)(O)OCC[N+]1(C)CCC=C(C(=O)OC)C1)OC | [
"anti tumor",
"anti microbial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a phosphodiesterase inhibitor. | COc1ccc2c(C)c3c(c(-c4ccc(F)cc4)c2c1)C(=O)NC3=O | [
"phosphodiesterase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts barth syndrome and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts non-alcoholic fatty liver disease, aging, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Barth syndrome",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Aging",
"Cholesterol translocation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and smooth, impacting both diabetic heart disease and aging. The molecule is a energy storage and a apoptosis that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, emulsifier, surfactant, membran... | CCC(C)CCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Aging",
"Smooth",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Energy storage",
"Apoptosis",
"Cholesterol translocation",
"Emulsifier",
"surfactant",
"Membrane stabilizer",
"Proton trap for oxidative... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a rsv inhibitor. | C#Cc1cnc(C(=N)OC(N)=NC2N=C(c3ccccc3)c3ccccc3NC2=O)c(N2CCOCC2)c1 | [
"rsv inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pi3 kinase inhibitor and is anti cancer agent. | CN(C)CCNC(=O)c1cccc(-c2cccc(Oc3cc(=O)[nH]c4ccccc34)c2)c1 | [
"anti cancer agent",
"pi3 kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein tyrosine phosphatase inhibitor. | CCCCCCc1ccc(-n2c(C)ccc2-c2ccc(OC(Cc3ccccc3)C(=O)O)cc2)cc1 | [
"protein tyrosine phosphatase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both metabolic syndrome and pancreatitis. The molecule is a fat storage that impacts thyroxine treatment, atherosclerosis, and cardiovascular disease. | CCCC/C=C\CCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"nutrient",
"Metabolic syndrome",
"Pancreatitis",
"Thyroxine treatment",
"Atherosclerosis",
"Cardiovascular disease",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the photosensitive class of molecules. | COS(=O)(=O)[O-].Cc1ccc(N2NC(c3ccccc3)=N[NH+]2c2ccccc2)cc1 | [
"photosensitive"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, aging, tangier disease, and barth syndrome. The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation that impacts diabetic heart disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis, cholesterol translocation. It impacts diabetic heart disease, barth syndrome, tangier disease, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts celiac disease, heart failure, cardiovascular disease, and inflammatory bowel disease. The molecule is a energy source that affects breast cancer by impacting both renal cell carcinoma and diabetes mellitus type 2. | CCCCCCCCCCCCCCCCCCCCCC(C)CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Celiac disease",
"Heart failure",
"Cardiovascular disease",
"Inflammatory bowel disease",
"Renal cell carcinoma",
"Diabetes mellitus type 2",
"Energy source",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti body. | Cc1c(-c2ccc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)cnn1CC12CC3(C)CC(C)(C1)CC(OCCN(CCC(O)O)C(=O)OCc1ccc(NC(=O)C(C)NC(=O)C(NC(=O)CCCCCN4C(=O)C=CC4=O)C(C)C)cc1)(C3)C2 | [
"anti body"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts aging, tangier disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Aging",
"Tangier disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both thyroxine treatment and cardiovascular disease. The molecule is a nutrient that impacts metabolic syndrome, atherosclerosis, and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Fat storage",
"Thyroxine treatment",
"Cardiovascular disease",
"Metabolic syndrome",
"nutrient",
"Atherosclerosis",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts non-alcoholic fatty liver disease. The molecule is a cholesterol translocation that impacts barth syndrome, tangier disease, diabetic heart disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Barth syndrome",
"Tangier disease",
"Diabetic heart disease",
"Aging",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti tumor and anti cancer. | COC(C(=O)NC(C)C(=O)NCCOC(=O)C12CC3CC(CC(C3)C1)C2)C(O)C(O)C(O)C=CC(C)(C)C | [
"anti tumor",
"anti cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and thyroxine treatment, and it impacts atherosclerosis. The molecule is a nutrient that impacts pancreatitis, cardiovascular disease, and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCC/C=C\CCCC | [
"Atherosclerosis",
"Thyroxine treatment",
"Fat storage",
"Pancreatitis",
"Cardiovascular disease",
"nutrient",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy storage, inflammatory, energy source that has an effect on lipotoxicity and impacts metabolic syndrome. | CCCCCCCCCCCCCC(=O)OC[C@H](O)COC(=O)CCCCCCCCC(C)C | [
"Membrane stabilizer",
"Energy storage",
"inflammatory",
"Metabolic syndrome",
"Lipotoxicity",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and aging. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts barth syndrome and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts barth syndrome and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Tangier disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts aging and tangier disease. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule has Aromatic odor (technical). When heated to decomposition it emits acrid smoke and irritating fumes. | O=C1c2ccccc2C(=O)c2ccccc21 | [
"Odor_evaluation",
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is cystic fibrosis treatment and anti fungal. | CCC(C)C1CC=CC=CC=CC=CC=CC(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)C(O)CCC(=O)CC(O)CC(=O)O1)CC(O)C2C(=O)O | [
"cystic fibrosis treatment",
"anti fungal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects breast cancer by impacting ulcerative colitis, atherosclerosis, and cervical cancer. | CCCCC/C=C\C/C=C\C=C\C=C\[C@@H](SC[C@H](N)C(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCC)[C@@H](O)CCCC(=O)O | [
"nutrient",
"Ulcerative colitis",
"Atherosclerosis",
"Cervical cancer",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is fluorescent and phosphorescent. | CC(CS)c1ccc2c(c1)N1c3ncccc3Sc3cccc(c31)S2=O | [
"fluorescent",
"phosphorescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cdk inhibitor. | CC(C)N1CCOc2c(F)cc(-c3cn(C)c(Nc4ccc(N5CCN(S(C)(=O)=O)CC5)cn4)n3)cc21 | [
"cdk inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule has Odorless. Dt50 1-7 days (ph 7), <1 hr (ph 9). aqueous solns degraded by uv light. | CC(C)NC(=O)N1CC(=O)N(c2cc(Cl)cc(Cl)c2)C1=O | [
"Odor_evaluation",
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, tangier disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and fat storage, and it impacts cardiovascular disease. The molecule is thyroxine treatment and impacts metabolic syndrome, atherosclerosis, and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Fat storage",
"Cardiovascular disease",
"Thyroxine treatment",
"Metabolic syndrome",
"Atherosclerosis",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease. The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts aging and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a environmental contaminant, air pollutant, mutagen, hazardous air pollutant, water pollutant with a ... strong, ammonia-like odor .... | NCCNCCN | [
"environmental contaminant",
"Air pollutant",
"mutagen",
"Hazardous air pollutant",
"Water pollutant",
"Odor_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both metabolic syndrome and pancreatitis. The molecule is a nutrient and a thyroxine treatment, impacting both cardiovascular disease and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OCC(COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Metabolic syndrome",
"Fat storage",
"Pancreatitis",
"Cardiovascular disease",
"nutrient",
"Thyroxine treatment",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pain treatment. | CC(C)C(CN1CCCC1)NC(=O)C1(c2cnc3ccccc3c2)CC1.Cl | [
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, diabetes mellitus type 2, parkinson's disease, and non-alcoholic fatty liver disease. | CCCCCC/C=C\CCCCCCCC/C=C/OC[C@H](COP(=O)(O)OCCN)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCO | [
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is organic electroluminescent and electroluminescent. | c1ccc(-c2cc(-c3ccccc3)nc(-n3c4ccccc4c4cc(-c5ccc6c7ccccc7n(-c7ccc8c(c7)c7ncncc7n8-c7ccccc7)c6c5)ccc43)n2)cc1 | [
"organic electroluminescent",
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase that impacts barth syndrome, diabetic heart disease, tangier disease, and aging. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the androgen receptor modulator class of molecules. | CN1C(=O)C=CC2(C)C3CCC4(C)C(O)CCC4C3CC(=Cc3cccc(C(=O)O)c3)C12 | [
"androgen receptor modulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC(C)C12C=CC(C)(O)C1C2 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, barth syndrome, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Tangier disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.